Discoveries About Antibodies Provide Hope For Cancer Prevention

by Rachel on May 16, 2010

Commitment and perseverance are the tools over the last thirty years, will be used to develop and approve antibodies for cancer prevention. Monoclonal antibodies, or “Mabs”, the result of hours of medical researchers in the long and arduous behind microscopes have been perfect in the hope of using these cells for cancer doctors in the world. What discoveries did a lot for cancer patients, especially as the number of people in the United States with some form of cancer diagnosed each year continues to increase. The use of MABS, doctors and health practitioners will be another weapon against the deadly silent killers like cancer but known to use. The American Cancer Society (AMC) website explains that monoclonal antibodies have been developed in the laboratory mice with myeloma cells, producing a type of cancer of the bone marrow, and mice, antibodies specific for these cells . The combination of these two cells, called hybridomas, an eternal power plant for the antibodies. Antibodies to the end identified as identical clones of the original hybridoma cell line, which is why they are monoclonal antibodies. The problem scientists face these phenomenal results that antibodies to the man of the mouse antibody as foreign invaders and attacked them recognized. With hard work and dedication are the scientists continue to develop ways to integrate human antibodies instead of mouse antibodies as cancer patients, immunotherapy can be used as a form of treatment. Today, there are two types of MABS, naked and conjugated. The difference between the two lies in the fact that naked antibodies radioactive materials associated with them absent. conjugated antibodies, on the other hand, with a chemotherapeutic agent or other toxins used to fight cancer cells by fusion. In recent years, the Food and Drug Administration (FDA) has several MABS, both naked and conjugated approved for the treatment of cancer. A list of approved Mabs are available on the ACA web site. In the years 2004 and 2006, bevacizumab, naked antibody, was approved for the treatment of certain types of breast cancer. In 2001, the FDA approved the use of Alemuzumab, a naked antibody, which acts as a form of leukemia prevention by both B-and T-cell cancer that attacks the body’s immune system and kill . In 2000, the FDA approved the use of an antibody conjugate, gemtuzumab ozogamicin, which is used in the treatment of chronic leukemia. Every cancer year claims thousands of victims. Results of Pharmaceutical Research and Manufacturers of America show that more than 200,000 women diagnosed with breast cancer, about 150,000 men and women who die of colorectal cancer and more than 30,000 men with prostate cancer will be diagnosed this year . Given these figures, it is not difficult to understand why the use and ongoing research by mAb essential to our society. are the recent approval of a vaccine used to protect women against human papillomavirus, a known connection with the development of cancer of the cervix, shows that the research laboratories to help the dawn see Antibodies for the prevention of cancer, offering hope that the number of cancer patients began to decrease. experience success often outweighs the failures that scientists and drug researchers, if they succeed in finding cures for cancer and other deadly diseases. The victories in recent decades have come in the form of antibodies for the prevention of cancer. MABS that receiving approval from the FDA, are now used in the treatment of cancer patients worldwide. Over time, these treatments are developed and refined the way to assist in the protection and treatment of cancer for future generations.

Andi Michaels has worked in the health sector and now manages sites related to health topics like cancer and asbestosis on websites

Leave a Comment

Previous post:

Next post: